{"id":43965,"date":"2026-01-08T20:34:00","date_gmt":"2026-01-08T13:34:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=43965"},"modified":"2026-01-08T20:34:00","modified_gmt":"2026-01-08T13:34:00","slug":"illumina-and-premia-partner-to-expand-clinical-access-to-cgp-in-asia","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=43965","title":{"rendered":"Illumina and PREMIA partner to expand clinical access to CGP in Asia"},"content":{"rendered":"

TAIPEI<\/span><\/span>, Jan. 8, 2026<\/span><\/span> \/PRNewswire\/ — Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a leading Asian cancer clinical-genomic screening network, today announced the formation of a strategic partnership that will expand access to comprehensive genomic profiling (CGP) for all eligible oncology patients across the Chang Gung<\/span> Memorial Hospital (CGMH) system. This partnership also aims to support the creation of an Asia<\/span>-wide clinical-genomic oncology database to advance precision oncology.<\/p>\n

“We are committed to ensuring that all cancer patients benefit from the most advanced medical science available,” stated Dr. Chang-Fu Kuo<\/span>, Director of the Center for Artificial Intelligence in Medicine at CGMH. “Integrating CGP will streamline our testing workflows and help clinicians gain a better understanding of each patient’s tumor biology, enabling them to routinely consider key genomic insights alongside clinical judgement and established guidelines to provide patients with more informed and personalized treatment plans.”<\/p>\n

Chang Gung<\/span> Memorial Hospital, one of Taiwan’s<\/span> leading healthcare systems and medical centers serving approximately 2.7 million patients each year, with over 300 industry-sponsored clinical trials currently ongoing throughout the system, has long been dedicated to translating cutting-edge technologies into clinical practice.<\/p>\n

Jerry Cheng<\/span>, General Manager for Taiwan<\/span>, Hong Kong<\/span> and Macao<\/span> at Illumina, added, “Illumina remains at the forefront of advanced oncology profiling solutions, empowering clinicians to gain clinically and scientifically meaningful insights faster. This partnership will accelerate personalized care decisions at CGMH, and through the depth and scale of data generated over time, together with clinicians and industry partners, we look forward to supporting translational research and drug development across Asia<\/span>.”<\/p>\n

In May 2024,\u00a0CGP was incorporated into Taiwan’s<\/span> National Health Insurance (NHI) program.<\/p>\n

About Illumina<\/b>\u00a0<\/p>\n

Illumina is improving human health by unlocking the power of the genome. Our focus on\u00a0innovation has\u00a0established\u00a0us as a global leader\u00a0in\u00a0DNA sequencing and array-based technologies, serving customers\u00a0in\u00a0the research, clinical, and applied markets. Our products are used for applications\u00a0in\u00a0the life\u00a0sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit\u202fillumina.com<\/span><\/a>\u202fand connect with us on\u202fX<\/a>,\u202fFacebook<\/a>,\u202fLinkedIn<\/a>,\u202fInstagram<\/a>,\u202fTikTok<\/a>, and\u202fYouTube<\/a>.<\/span><\/p>\n

About Precision Medicine Asia\u00a0(Taiwan<\/span>) Limited\u00a0(PREMIA)<\/b>\u00a0<\/p>\n

Established\u00a0in\u00a02018,\u00a0PREMIA\u00a0is the first company\u00a0in\u00a0Asia to collaborate with\u00a0hospitals\u00a0in\u00a0the region by providing a clinical-genomic data management platform that helps accelerate development of\u00a0innovative therapeutics and diagnostics.\u00a0Along with these activities,\u00a0PREMIA is dedicated to\u00a0forming\u00a0partnerships\u00a0with biopharmaceutical and healthcare technology companies,\u00a0worldwide,\u00a0to\u00a0improve efficiencies and\u00a0expand access to\u00a0novel\u00a0medicines and health-tech solutions\u00a0for patients.\u00a0For more\u00a0information, please visit\u00a0www.premia-inc.com<\/a>.\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

TAIPEI<\/span><\/span>, Jan. 8, 2026<\/span><\/span> \/PRNewswire\/ — Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a leading Asian cancer clinical-genomic screening network, today announced the formation of a strategic partnership that will expand access to comprehensive genomic profiling (CGP) for all eligible oncology patients across the Chang Gung<\/span> Memorial Hospital (CGMH) system. This partnership also aims to support the creation of an Asia<\/span>-wide clinical-genomic oncology database to advance precision oncology.<\/p>\n

“We are committed to ensuring that all cancer patients benefit from the most advanced medical science available,” stated Dr. Chang-Fu Kuo<\/span>, Director of the Center for Artificial Intelligence in Medicine at CGMH. “Integrating CGP will streamline our testing workflows and help clinicians gain a better understanding of each patient’s tumor biology, enabling them to routinely consider key genomic insights alongside clinical judgement and established guidelines to provide patients with more informed and personalized treatment plans.”<\/p>\n

Chang Gung<\/span> Memorial Hospital, one of Taiwan’s<\/span> leading healthcare systems and medical centers serving approximately 2.7 million patients each year, with over 300 industry-sponsored clinical trials currently ongoing throughout the system, has long been dedicated to translating cutting-edge technologies into clinical practice.<\/p>\n

Jerry Cheng<\/span>, General Manager for Taiwan<\/span>, Hong Kong<\/span> and Macao<\/span> at Illumina, added, “Illumina remains at the forefront of advanced oncology profiling solutions, empowering clinicians to gain clinically and scientifically meaningful insights faster. This partnership will accelerate personalized care decisions at CGMH, and through the depth and scale of data generated over time, together with clinicians and industry partners, we look forward to supporting translational research and drug development across Asia<\/span>.”<\/p>\n

In May 2024,\u00a0CGP was incorporated into Taiwan’s<\/span> National Health Insurance (NHI) program.<\/p>\n

About Illumina<\/b>\u00a0<\/p>\n

Illumina is improving human health by unlocking the power of the genome. Our focus on\u00a0innovation has\u00a0established\u00a0us as a global leader\u00a0in\u00a0DNA sequencing and array-based technologies, serving customers\u00a0in\u00a0the research, clinical, and applied markets. Our products are used for applications\u00a0in\u00a0the life\u00a0sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit\u202fillumina.com<\/span><\/a>\u202fand connect with us on\u202fX<\/a>,\u202fFacebook<\/a>,\u202fLinkedIn<\/a>,\u202fInstagram<\/a>,\u202fTikTok<\/a>, and\u202fYouTube<\/a>.<\/span><\/p>\n

About Precision Medicine Asia\u00a0(Taiwan<\/span>) Limited\u00a0(PREMIA)<\/b>\u00a0<\/p>\n

Established\u00a0in\u00a02018,\u00a0PREMIA\u00a0is the first company\u00a0in\u00a0Asia to collaborate with\u00a0hospitals\u00a0in\u00a0the region by providing a clinical-genomic data management platform that helps accelerate development of\u00a0innovative therapeutics and diagnostics.\u00a0Along with these activities,\u00a0PREMIA is dedicated to\u00a0forming\u00a0partnerships\u00a0with biopharmaceutical and healthcare technology companies,\u00a0worldwide,\u00a0to\u00a0improve efficiencies and\u00a0expand access to\u00a0novel\u00a0medicines and health-tech solutions\u00a0for patients.\u00a0For more\u00a0information, please visit\u00a0www.premia-inc.com<\/a>.\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"class_list":["post-43965","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/43965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43965"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/43965\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}